Tang Libo, Li Ruiyang, Wen Huahai, Zhou Qing, Xu Chongrui
School of Medicine, South China University of Technology, Guangzhou, Guangdong 510080, China.
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong 510080, China.
Chin Med J Pulm Crit Care Med. 2023 Jun 28;1(4):207-214. doi: 10.1016/j.pccm.2023.04.001. eCollection 2023 Dec.
Lung cancer is the second most common cancer worldwide and the leading cause of cancer-related fatalities, with non-small cell lung cancer (NSCLC) accounting for 85% of all lung cancers. Over the past forty years, patients with NSCLC have had a 5-year survival rate of only 16%, despite improvements in chemotherapy, targeted therapy, and immunotherapy. Circulating tumor DNA (ctDNA) in blood can be used to identify minimal residual disease (MRD), and ctDNA-based MRD has been shown to be of significance in prognostic assessment, recurrence monitoring, risk of recurrence assessment, efficacy monitoring, and therapeutic intervention decisions in NSCLC. The level of MRD can be obtained by monitoring ctDNA to provide guidance for more precise and personalized treatment, the scientific feasibility of which could dramatically modify lung cancer treatment paradigm. In this review, we present a comprehensive review of MRD studies in NSCLC and focus on the application of ctDNA-based MRD in different stages of NSCLC in current clinical practice.
肺癌是全球第二大常见癌症，也是癌症相关死亡的主要原因，其中非小细胞肺癌（NSCLC）占所有肺癌的85%。在过去四十年中，尽管化疗、靶向治疗和免疫治疗有所改善，但NSCLC患者的5年生存率仅为16%。血液中的循环肿瘤DNA（ctDNA）可用于识别微小残留病（MRD），基于ctDNA的MRD已被证明在NSCLC的预后评估、复发监测、复发风险评估、疗效监测和治疗干预决策中具有重要意义。通过监测ctDNA可以获得MRD水平，为更精确和个性化的治疗提供指导，其科学可行性可能会极大地改变肺癌治疗模式。在本综述中，我们对NSCLC中MRD的研究进行了全面综述，并重点关注基于ctDNA的MRD在当前临床实践中NSCLC不同阶段的应用。
